Skip to content

Gelweave™ 73301088/8Recalls & reported problems

Vascutek Ltd · Gelweave Gelatin Impregnated Woven Vascular Prosthesis 4 BRANCH PLEXUS · Class 2 · Implant

All models of Gelweave (47)

Data updated Oct 16, 2026 from official FDA records · Editorial policy

Adverse event reports
1
Deaths reported
0
Injuries reported
0
Recalls naming it
0

Summary

The FDA's MAUDE database contains 1 adverse event report that list this exact device (DI 05037881106359), received between Jul 23, 2020 and Jul 23, 2020 — classified as 1 malfunction.

The most frequently reported specific device problem is “Device Handling Problem” (1 report).

1 other recall cover devices cleared under the same FDA submission (K090987, K162794); they may or may not involve this specific model.

Reports come from manufacturers, hospitals and patients and are not verified by the FDA. A report does not prove the device caused the event, and counts can't be used to compare devices or estimate failure rates. What reports can and can't tell you · How this data works · Data updated Oct 16, 2026.

Most reported problems

Device problems

  • Device Handling Problem1
  • Use of Device Problem1

Patient problems

  • Aneurysm1
  • Aortic Dissection1

Recent adverse event reports

The 1 most recent of 1 reports, in the reporter's own words as published by the FDA.

  • MalfunctionJul 23, 2020Use of Device Problem; Device Handling Problem; Use of Device Problem; Device Handling Problem

    PATIENT ADMITTED FOR ACUTE TYPE A DISSECTION DEBAKEY TYPE I BASED ON A PRE-EXISTING ASCENDING ANEURYSM, NO ANTICOAGULATION TREATMENT IN MEDICAL HISTORY, EMERGENT ARCH REPLACEMENT. PATIENT UNDERWENT AORTIC ARCH REPLACEMENT UNDER HYPOTHERMIC CIRCULATORY ARREST (25 °C) AND BILATERAL ANTEGRADE CEREBRAL PERFUSION. AFTER WEANING FROM CARDIOPULMONARY BYPASS AND ADEQUATE SUBSTITUTION OF PROTAMINE, PROGRESSIVE LEAKAGE OF PROSTHESIS IN THE AREA OF FIRST SIDE BRANCH OF PLEXUS PROSTHESIS AND ALONG BLACK SUTURE MARK OF MAIN BODY. CLINICAL RELEVANT BLOOD LOSS, DESPITE MASSIVE SUBSTITUTION OF FIBRINOGEN, THROMBOCYTES, PROTAMINE, DESMOPRESSIN AND FRESH FROZEN PLASMA NO IMPROVEMENT OF LEAKAGE OVER THREE HOURS. ADDITIONAL LOCAL FIBRIN GLUE AND OTHER HEMOSTYPTIC MATERIAL APPLIED ON TOP OF PROSTHETIC MATERIAL. AFTER WOUND CLOSURE NO RELEVANT BLEEDING, PATIENT IS EXTUBATED AND CLINICAL STABLE. PATIENT RECEIVED MASSIVE SUBSTITUTION OF BLOOD AND COAGULATION PRODUCTS BUT TOLERATED ALL VERY WELL. OPERATIVE TIME WAS PROLONGED BUT PATIENT RECOVERED UNEVENTFUL.

    Patient problems: Aneurysm; Aortic Dissection

    MAUDE report 10312145 ↗

Recalls under the same FDA submission

These recalls involve devices cleared under K090987, K162794. One submission often covers many models, so check the product and lot details in each record.

  • Z-2542-2021 · Jul 8, 2021 · Terminated
    The Instructions for Use (IFU) for: Gelsoft Plus Bifurcate, Gelsoft Plus Ax-Fem, GelsoftPlus ERS Ax-Fem, Gelweave Straight, Gelweave Trifurcate, Gelweave Ant-Flo, and Gelweave Val

Other PROSTHESIS, VASCULAR GRAFT, OF 6MM AND GREATER DIAMETER devices

All PROSTHESIS, VASCULAR GRAFT, OF 6MM AND GREATER DIAMETER devices →

Sources and updates

How reports and recalls are matched · Editorial policy · Report an error on this page